Lonza reports that it will invest to expand mammalian development services in Singapore. The increased service capabilities are intended to complement the existing offering, consisting of cell line construction services, process development, and process characterization services at the mammalian and cell therapy manufacturing site in Singapore. The investment will expand the current laboratory capabilities by establishing a new 1,800m2 lab at Singapore Science Park, increasing the headcount of the mammalian development services team in Singapore to 125 employees. Source: Genetic Engineering News 7/10/2021